Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoBio Launches Development Program for a Therapeutic Intranasal Vaccine for the Treatment of Hepatitis B

Abstract:
NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients. This development program represents the first of several potential therapeutic vaccines in a significant extension of NanoBio's vaccine platform.

NanoBio Launches Development Program for a Therapeutic Intranasal Vaccine for the Treatment of Hepatitis B

Ann Arbor, MI | Posted on April 22nd, 2010

Hepatitis B is an infection of the liver caused by the HBV virus. HBV is the most common cause of chronic viral liver disease worldwide. More than 370 million people are chronically infected with hepatitis B, leading to nearly one million deaths annually as a result of cirrhosis, and liver failure. HBV is transferred via bodily fluids and blood, and is commonly spread through sexual intercourse and intravenous drug use. Today, vaccinations are routinely given to infants to prevent infection contributing to lower rates of incidence in recent years. However, for patients previously infected, recurring infection is a concern that cannot be mitigated with existing vaccines.

"Currently available HBV vaccines are effective prophylactics, but lack therapeutic properties for those that are already infected," said James R. Baker, MD, CEO and founder of NanoBio. "This new intranasal vaccine would have great value as a treatment to reduce the risk of HBV associated liver diseases and deaths globally. The vaccine is also highly stable at room temperature enabling storage without refrigeration, a factor of great importance in the developing world."

Through this project, NanoBio and University of Michigan teams will demonstrate in animals the capabilities of a nanoemulsion-based HBV vaccine to safely induce immune responses in the presence of confounding factors such as kidney failure. This research is especially important as individuals with kidney function deficiencies are at high risk for complications of HBV infection when compared to normal individuals.

After successful completion of the preclinical studies funded by this STTR, NanoBio plans to conduct a FDA-approved Phase 1 clinical trial to evaluate safety, dose range, immunogenicity and preliminary efficacy against chronic HBV in humans with kidney failure.

####

About NanoBio Corporation
NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

About NanoBio’s Vaccine Platform
NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The company’s NanoStat™ adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.

For more information, please click here

Contacts:
V.P. Business Development:
John Coffey (Ext. 107)

Copyright © NanoBio Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Govt.-Legislation/Regulation/Funding/Policy

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Researchers find new way to control light with electric fields May 25th, 2017

Academic/Education

MIT Energy Initiative awards 10 seed fund grants for early-stage energy research May 4th, 2017

Bar-Ilan University to set up quantum research center May 1st, 2017

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

SUNY Polytechnic Institute Announces Total of 172 Teams Selected to Compete in Solar in Your Community Challenge: Teams from 40 states, plus Washington, DC, 2 Territories, and 4 American Indian Reservations, Will Deploy Solar in Underserved Communities April 20th, 2017

Nanomedicine

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Sensors detect disease markers in breath May 19th, 2017

Announcements

Ag/ZnO-Nanorods Schottky diodes based UV-PDs are fabricated and tested May 26th, 2017

New metamaterial-enhanced MRI technique tested on humans May 26th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

Unveiling the quantum necklace: Researchers simulate quantum necklace-like structures in superfluids May 26th, 2017

Nanobiotechnology

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Sensors detect disease markers in breath May 19th, 2017

Oddball enzyme provides easy path to synthetic biomaterials May 17th, 2017

The brighter side of twisted polymers: Conjugated polymers designed with a twist produce tiny, brightly fluorescent particles with broad applications May 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project